CYCC - Cyclacel Pharmaceuticals prices $12.65M underwritten public offering

Cyclacel Pharmaceuticals (CYCC) announces the pricing of an underwritten public offering of 1.8M shares at $7/share with expected gross proceeds of $12.65M.Intends to use the net proceeds to support the company’s growth strategy and for working capital and general corporate purposes, including research and development expenses, and capital expenditures.Has granted the underwriters a 30-day option to purchase up to an additional 271K shares, offering is expected to close on or about March 16, 2021.

For further details see:

Cyclacel Pharmaceuticals prices $12.65M underwritten public offering